Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a devastating and fatal chronic lung disease. While current pharmacotherapies have improved patient quality of life, PAH drugs suffer from limitations in the form of short-term pharmacokinetics, instability, and poor organ specificity. Traditionally, nanotech...

Descripción completa

Detalles Bibliográficos
Autores principales: Segura-Ibarra, Victor, Wu, Suhong, Hassan, Nida, Moran-Guerrero, Jose A., Ferrari, Mauro, Guha, Ashrith, Karmouty-Quintana, Harry, Blanco, Elvin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055049/
https://www.ncbi.nlm.nih.gov/pubmed/30061840
http://dx.doi.org/10.3389/fphys.2018.00890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055049/
https://www.ncbi.nlm.nih.gov/pubmed/30061840
http://dx.doi.org/10.3389/fphys.2018.00890

Ejemplares similares